Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Barinthus Biotherapeutics (BRNS) EBT Margin (2020 - 2026)

Barinthus Biotherapeutics (BRNS) has disclosed EBT Margin for 7 consecutive years, with 16818.18% as the latest value for Q1 2026.

  • For Q1 2026, EBT Margin fell 1059033.0% year-over-year to 16818.18%; the TTM value through Mar 2026 reached 154420.59%, down 15399304.0%, while the annual FY2024 figure was 409.03%, 913237.0% up from the prior year.
  • EBT Margin hit 16818.18% in Q1 2026 for Barinthus Biotherapeutics, up from 2115100.0% in the prior quarter.
  • Across five years, EBT Margin topped out at 122.42% in Q3 2022 and bottomed at 2115100.0% in Q2 2025.
  • Average EBT Margin over 5 years is 214981.61%, with a median of 2181.54% recorded in 2022.
  • On a YoY basis, EBT Margin climbed as much as 4821516bps in 2022 and fell as far as -166895902bps in 2022.
  • Barinthus Biotherapeutics' EBT Margin stood at 359.02% in 2022, then plummeted by -1982bps to 7473.05% in 2023, then surged by 99bps to 54.33% in 2024, then tumbled by -3893276bps to 2115100.0% in 2025, then soared by 99bps to 16818.18% in 2026.
  • According to Business Quant data, EBT Margin over the past three periods came in at 16818.18%, 2115100.0%, and 6227.85% for Q1 2026, Q2 2025, and Q1 2025 respectively.